A Phase I Study Evaluating the Safety, Tolerability, Biodistribution and Shedding of Oncolytic Vaccinia Virus GC001, Pharmacodynamics, Immunogenicity, and Antitumor Activity of the Virus in Patient With Recurrent or Progressive Gliomas
Latest Information Update: 30 Oct 2024
At a glance
- Drugs GC 001 (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Hangzhou Gongchu Biotechnology
Most Recent Events
- 30 Oct 2024 New trial record